Ductal Carcinoma in situ of the female Breast by Mohamed, Elgaili et al.
EDITORIAL  
Gezira Journal Of Health Sciences 2007 vol.3(2)  
 
)23(vol. 7Gezira Journal Of Health Sciences 200 
 
Ductal Carcinoma in situ of the female Breast 
 
Dr. Elgaili Mohamed,   Prof A.A. Mohammadani, Dr. Mukhtar Elkhatim. 
 
Panoramic View: 
The breast is the most common site of cancer in females in many parts of the world. Mammary 
carcinoma is either ductal arising from ducts or lobular arising from lobules. When ductal carcinoma is still 
confined to the mother duct it is called ductal carcinoma in situ "DCIS" & when confined to the lobules it 
is called lobular carcinoma in situ "LCIS". 
 
Historical Review: 
Comedo carcinoma was the first type of DCIS identified in 1893. Bloodgood wrote “I assisted Dr. 
Halsted in exploring a clinically benign tumour of the breast. The moment we cut into & pressed on it, there 
exuded from its surface many greyish white granular cylinders which I called at that time comedos. From 
the gross appearance, the tumour was diagnosed as malignant and the radical operation was performed. The 
nodes were not involved(1). 
Micrographs of other forms of what we would now call DCIS appeared in the literature in the 1900s. 
These included papillary, micropapillary and cribriform carcinomas that formed palpable masses judged to 
be malignant on gross examination (2). 
In 1911, William McCarty raised on a genius question by asking: Is it necessary to wait for the 
penetration of the basement membrane before making a diagnosis of carcinoma? (3). In 1913, he published 
a paper that illustrated the cytological differences between normal cells & those of invasive carcinoma. He 
illustrated comedocarcinoma & convincingly demonstrated that the abnormal cells in the ducts were 
cytologically identical to those of the invasive carcinoma (4).  
In all editions of Ewing's book "Neoplastic Diseases"(5), first published in 1919, he illustrated a case 
of lobular carcinoma in situ "LCIS" and referred to is as precancerous. In the subsequent editions, he 
illustrated two photomicrographs of DCIS, one is a cribriform/micropapillary & the other is a 
comedocarcinoma. In his final 4th edition, in 1940, he explained that these tumours grow in distended ducts 
over considerable segments of the breast. Such tumours are slow to involve the lymph nodes but eventually 
they break through the basement membrane & infiltrate the fat & connective tissue in the form of alveolar 
carcinoma, his term for infiltrating ductal carcinoma. 
The term cribriform carcinoma was well established by 1933 when Schultz-Brauns (2) illustrated the 
sieve-like type of cribriform DCIS by a drawing as well as a photograph. 
The concept of preinvasive carcinoma of the human breast was firmly established in the United 
Kingdom by the early 1930s. In 1933, the pathologist Dawson (6) concluded that carcinoma always arose in 
ducts and "in the majority of cases in the terminal intralobular ducts". She also recongnised cancerisation 
of the individual lobular ductules concluding that "involvement of the lobules is not primary but secondary, 
and is evidence of extension of the cancerous process". Her major conclusions are based on meticulous 
review of normal and abnormal breast. 
In 1932, Brooders (7), coined the phrase carcinoma in situ. He demonstrated examples of five organs, 
one of which was a breast lobule that he called “Adenocarcinoma in situ”. His photograph is an indubitable 
example of what became known in 1941 as lobular carcinoma in situ (8, 9). 
In 1935, Muir, a Scottish pathologist might have been the first to use the term intraduct carcinoma. 
He noted that proliferating ductal epithelial cells have acquired the essential characters of malignant 
neoplasia and they acquire this character before they transgress the normal boundaries (8). 
In 1934 Foote and Stewart, pathologists at the Memorial Hospital for Cancer and Allied Diseases, 
wrote papers covering benign and malignant conditions of the breast (9, 10). In one paper, they illustrated a 
lesion diagnosed as "non infiltrating papillary carcinoma" that is cytologically and architecturally identical 
to their illustration of an infiltrating papillary carcinoma. They observed that the individual cells are usually 
of medium size and they do not vary a great deal in configuration and stainability. Hyperchromatism is not 
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impressive and the rate of cell division is low". Using today's terminology, their intraductal carcinoma is a 
cribriform DCIS and the infiltrating lesion is an infiltrative cribriform carcinoma. The difficulty of 
diagnosing intraductal lesions is evident in their statements "there is a zone of altered cell growth where the 
diagnosis of carcinoma versus atypical papillomatosis is a question of occult distinction and must be 
accepted or rejected on grounds of faith in the pathologist or lack of it". 
Stewart who wrote the first edition of the Armed Forces Institute of Pathology Tumour Fascicle on 
Breast published in 1950 (10), used the photomicrograph of papillary intraductal carcinoma from the 1945 
paper and added four other illustrations diagnosed as papillary cancer. In the legend of figure 17 in Stewart 
book, the term in situ ductal carcinoma "DCIS" was used for the first time. The statement regarding occult 
distinction and faith was reiterated. 
In the first edition, 1953, of his classic textbook on surgical pathology (11) Ackerman illustrated 
comedocarcinoma as well as a true papillary carcinoma with fibrovascular stalks. During the 1950s and 
1960s, he was skeptic about the malignancy of intraductal lesions other than the ones that he illustrated. 
 
 
Pathology of DCIS 
 
These tumours of the ductal system are wholly confined within the basement membrane. They result 
from a disruption in the architecture of the breast glandular epithelium involving loss of the hollow lumen 
and epithelial cell proliferation in acinar units that occurs via an imbalance between apoptosis and 
proliferation (12). In the last several decades, the incidence of DCIS was raised from 5% to 20% of breast 
cancer (13, 14). 
Multicentric foci are present in about a third of cases and in about 10% the lesion is bilateral and 
2% are associated with Paget’s disease of the breast (15). Risk factors for invasive DCIS are similar to those 
for invasive carcinoma (13, 16, 17, 18, 19, 20, 21, 22 23, 24, 25, 26, 27). 
Ductal carcinoma in situ comprises several histological types; solid, cribriform, papillary, 
micropapillary and comedo. This histological classification does not take into account important prognostic 
features such as nuclear grade “high, intermediate or low”, necrosis “presence or absence” and polarization 
“architectural differentiation” (28, 29). Recently a number of classification systems have been proposed to 
standardize the diagnosis of DCIS “Table 1”. Almost all of them are based on the Bloom Richardson nuclear 
grading system. The cytological grading is advantageous over the histological grading because it offers a 
clue to the prognosis and clinical behaviour. Moreover more than one histological type can coexist in the 
same tumour.  
 
Solid DCIS: 
The duct is filled and distended with uniform medium sized cells. This uniformity of cell population, 
cytoplasm pallor and sharply outlined cell border are important diagnostic clues. The solid type of DCIS 
possesses the least propensity for evolving into invasive carcinoma (30). Differential diagnosis includes 
ordinary hyperplasia, florid ductal hyperplasia & atypical ductal hyperplasia. {Figures 1, 2, 3 & 4} 
 
 
 
Figure .1. Normal Hyperplasia 
 
                       
 
 
Figure .2. Florid epithelial hyperplasia 
 
EDITORIAL  
Gezira Journal Of Health Sciences 2007 vol.3(2)  
 
)23(vol. 7Gezira Journal Of Health Sciences 200 
 
 
Figure .3.Atypical ductal hyperplasia 
 
                      
 
Figure .4.Solid DCIS 
 
 
Comedo DCIS: 
                  This is the most common histological type of DCIS. Cytologically it is more anaplastic than the 
other subtypes. The central mass of cells degenerates and the bulk of the lumen becomes occupied by an 
amorphous mass of cell debris. This necrotic core can be expressed from large ducts in fresh specimens. 
Diagnosis is easy and no other lesion mimics this type of DCIS. {Figure 5} 
 
Cribriform DCIS: 
           The tumour cells are oriented into gland like formation with round lumina lined by rounded, cubical 
or columnar cancer cells and often containing a homogenous coagulum of secretion. The gland like spaces 
are more regular in shape more clearly delineated than in epitheliosis (17). {Figure 6} 
 
 
Figure .5.  Comedo DCIS 
 
Figure .6.  Cribriform DCIS 
 
Micropapillary DCIS: 
                         Dilated ducts with fingerlike papillary formation into the dilated lumina.  
Papillary DCIS: 
      Large papillary formation with fibrovascular stalks. This is the malignant counterpart of the intraduct 
papilloma. {Figure 7}. It is a rare form that occurs in old age group. Clinically papillary carcinoma and 
papilloma have similar features (17). Most commonly it arises de novo, but rarely can it arise within the 
context of multiple papilloma (31).  Sometimes it is very difficult to differentiate between papillary DCIS 
and ductal papilloma. Features fovaouring carcinoma are; uniformity in size and shape of the epithelial 
cells, presence of one cell type and lack of myoepithleial cells, nuclear hyperchromasia, high nuclear 
cytoplasmic ratio, high mitotic activity, lack of apocrine metaplasia, cribriform and trabecular patterns, 
scanty or absent stroma and lack of benign prolifeative disease in the adjacent breast. {Figure 7} 
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Figure .7. Intra ductal papilloma 
 
Evolution of DCIS: 
Intraductal epithelial proliferations of the breast are at present classified into three groups; usual 
epithelial hyperplasia, atypical ductal hyperplasia “ADH” and DCIS(43, 44). Studies suggested the transition 
from normal epithelia via hyperplasia and atypical hyperplasia to ductal carcinoma (43, 45). {Figures 8 and 
9}. Invasion does not occur in all cases and when it does so usually it takes years, the risk being directly 
proportional to the degree of cytological atypia (46). However, there are no clinical, morphological or 
biological indicators that sort out for sure those who will develop invasive cancer and no single factor so 
far seems to be particularly powerful in predicting progression (43). Two interesting phenomenon might be 
encountered in the course of evolution of DCIS to IDC. 
 
 
Figure .8: DCIS + IDC 
 
 
Figure.9. IDC + DCIS + Microcalcification
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Table 1 
Author and 
Reference 
Histological Variable DCIS categories 
Lagios(32). Nuclear grade, architecture and 
necrosis. 
High , intermediate and 
low grade 
Ottensen(33). Histological growth pattern, size of 
lesion, comedonecrosis and 
subhistological type. 
Microfocal, diffuse and 
tumour forming 
Bellamy(34). Histological pattern, nuclear grade, 
necrosis and involved duct counts. 
Comedo, solid, cribriform 
and micropapillary. All 
with nuclear grade. 
Poller(35). Architecture Comedo, DCIS with 
necrosis and DCIS without 
necrosis. 
Holland(36). Cytonuclear differentiation, 
architectural and cell polarization. 
Poorly differentiated, 
intermediately  and well 
differentiated. 
European breast 
screen group(37). 
Cytonuclear differentiation Poorly differentiated, 
intermediately & well 
differentiated.  
Page(38, 39). Architecture, nuclear grade and 
necrosis. 
Low, intermediate and 
high grade. 
Silverstein  and 
Van Nuys(40). 
Nuclear grade, comedo type and 
necrosis. 
Group 1: Non high grade 
without necrosis. 
Group 2: Non high grade 
with necrosis. 
Group 3: High grade. 
Consensus 
Committee(29). 
Architecture, polarization, necrosis 
and nuclear grade. 
Low, intermediate and 
high grade 
Tavassoli(41). Intraductal hyperplasia “IDH” and 
atypical ductal hyperpalais “ADH”. 
Ductal intraepithelial 
neoplasia “DIN” Grade 1, 
2 or 3.  
Warnberg(42). Histological grade, necrosis, 
lymphoid infiltration, mitosis, C-erb, 
P53, progesterone receptor, Bcl-2 
Phenotype A and B 
 
 
1. Microinvasion: 
Microinvasion is the forerunner of invasive ductal carcinoma. It is defined as predominently non-
invasive tumours in which there are one or more foci of infiltration, none measuring more than 1 mm in 
maximum diameter (47). DCIS with Microinvasion “DCISM” constitutes 0.68 – 2.4% of breast cancer and 
14% of DCIS (48, 49). The potential for DCISM should be suspected in comedo type, large size tumour and 
tumours with necrosis (50, 51 and 52).  Recognition of stromal micro invasion can be extremely difficult. The 
occurrence of stromal granulomatous reaction, though rare, may be a useful indicator of micro invasion in 
breast cancer (53).  
2. Intraepithelial spread:  
           Less commonly the malignant cells of DCIS, instead of penetrating the basement membrane to 
evolute into IDC, they spread intraepithelially either upward the duct towards the nipple to give rise to 
Paget’s disease of the breast or grow downward into the lobules to give rise to the so called cancerisation 
of the lobules. {Figure 10} 
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Figure .10: Paget's disease of the breast 
 
Page et al (54) provided a 24 yr follow up data for a cohort of 28 women with non comedo small 
DCIS who had been discovered as an incidental finding and not as a palpable mass. They received no 
therapy other than a surgical excision. Breast cancer developed in 10 out of 28 patients. 9 out of the 10 were 
invasive. 7 out of them developed the cancer within 10 yrs. 
Lagios et al (55) reported 79 patients with clinically occult DCIS measuring less than 25 mm treated 
by excision alone. With a mean follow up of 124 months, 13 patients developed recurrence “16%”. The 
recurrence was 33% for high grade DCIS compared to 2% for patients with intermediate & low grades 
DCIS. 
Bestill et al (56) from the Memorial Hospital in New York identified 25 cases with low grade 
papillary DCIS treated by excision alone. After a mean follow up of 21 yrs, 7 of 10 evaluable cases 
developed carcinoma, 6 of them were invasive.  
Solin et al (57) reported 172 patients treated with excision plus irradiation and followed for a median 
of 78 months. He observed that local recurrence in patients with grade III DCIS and comedo DCIS occurred 
earlier “38 months” than in other patients “78 months”. 
Silverstein et al (50) reported an 11% incidence of local recurrence in women with comedo DCIS 
compared with 2% in non comedo DCIS in 96 females followed up for 45 months. 
 
Current studies: 
          Several studies have addressed the prevalence of DCIS in the population. Kramer and Rush found 
that 6% of females above 70 yrs of age had DCIS & in half of the cases it is bilateral (58). Alpers and Welling 
(59) found an incidence of 9%. Nielsen et al (60) study on autopsies "20 – 54 yrs age" found an incidence of 
14%. Less than half of them were mammographically detectable. Howard et al (61) found a 10% false 
negative rate for DCIS which compares with the well known false negative rate of 15% for invasive 
carcinoma. 
A recent study was conducted by Rosai (62).  He selected 5 pathologists with special interest in 
pathology of the breast and sent the same 17 tissue slides to each of them. A small area was circled in ink, 
which assured that each pathologist diagnosed precisely the same field of a non-invasive epithelial 
proliferation. The diagnostic choices were limited to usual hyperplasia, atypical hyperplasia or carcinoma 
in situ. In none of the cases was there agreement by all pathologists. In only 3 cases did 4 of the pathologists 
agree and in only 9 cases did 3 out of 5 agree. Moreover 6 cases had diagnoses that spanned the spectrum 
of usual hyperplasia, atypical hyperplasia and carcinoma in situ. 
Schmitt et al (63) organised a similar study using 24 tissue slides of ductal proliferation. Before 
looking at the slides the six participating pathologists "3 of them participated in Rosai study" were given 
narrative and diagrammatic information regarding Page's criteria. Page circulated in tissue slides that he 
had diagnosed as usual hyperplasia, atypical hyperplasia or non comedo DCIS for review. After this 
preparation the study slides were sent out. All six pathologists agreed in 17 cases, and 4 of 6 pathologists 
agreed in 22 cases. The majority of discrepancies were between atypical hyperplasia and DCIS. Only two 
cases covered the spectrum of the 3 choices. 
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The fundamental problem regarding DCIS is the diagnosis of the non comedo types with low 
nuclear grade. Are there any aids beyond the H/E sections? Lodato et al (64) showed a strong membrane 
staining against C-erb B-2 in 10 out of 10 comedo DCIS, but only 1 out of 14 small cell micropapillary 
cribriform cases and it stained weakly. Bartkova et al (65) correlated C-erb B-2 protein positivity in different 
types of DCIS with nuclear cell size. Almost all of the comedo DCIS had large size “>20 microM” nuclei, 
whereas all of the cribriform, papillary & micropapillary DCIS had less than 10 microM in diameter. All 
of the comedos had positive staining, whereas none of the non comedos stained. Unfortunately, the use of 
these kinetic techniques & oncogens abnormalities does not help when help is needed the most. 
Till a sharp approach for the differential diagnosis of DCIS & epithelial hyperplasia show up & 
occult distinction between benign & malignant colours black & white, it is the duty of the unfortunate 
pathologist to make a distinction. 
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